Why the stem cells market will expand – discover its commercial potential
What does the future hold for stem cells in medicine? Visiongain’s report shows you potential revenues to 2022, assessing data, trends, opportunities and prospects there.
That new study lets you assess projected sales at world market and submarket level. You see discussions of work on stem cells in leading countries too – outlooks, challenges, patenting and regulations.
You see forecasting of world-level submarkets to 2022, finding potential revenues:
• Stem cell therapies
• Stem cell banks (e.g., cord blood banking)
• Ancillaries – adjunct technologies.
The technology is changing medicine through new therapies, methods and applications in drug development. Its scope is vast and promising, despite challenges.
With our study you also assess the R&D pipeline, seeing trends and outlooks. You find discussions of treatments in development, by therapeutic area and organization:
• Autoimmune diseases – modifying the immune system
• Diabetes – restoring pancreatic function
• Oncology and cancer treatment
• Cardiovascular diseases – healing the heart and vascular system
• Neurological and cerebrovascular disorders – regenerating CNS tissue
• Ophthalmic disorders – potential for overcoming sight loss
• Bioartificial livers and hepatic regeneration with stem and progenitor cells
• Dermatology – developments in cellular skin repair
• Adipose-derived stem cells for autologous treatments
• Regenerative dentistry – potential for biotechnological tooth replacement.
You find prospects for embryonic, adult and induced pluripotent stem cells from 2012.
Market value for 2014 and prospects for the future
What will happen next? The biotechnology industry will develop many products using stem cells and increase revenues there from 2012 to 2022. The R&D pipeline is extensive. Overall world revenue will reach $7.3bn in 2014, our report forecasts.
Expansion of the market will result from new stem cell treatments and increased uptake of those technologies in drug development assays.
A diverse pipeline of therapies offers hope for treating many diseases. There are potential cures for diabetes, HIV and dry age-related macular degeneration (AMD).
Stem cell-based innovations tackle cardiovascular disorders, autoimmune diseases, metabolic disorders and many other conditions. Some of the breakthroughs will be a commercial reality by 2022, our investigation predicts.
What are companies doing? Our work profiles 187 organisations and investigates prospects of the industry and market. Examples include these developers and producers:
• Advanced Cell Technology
• Baxter Healthcare
• Cytori Therapeutics
• Gamida Cell
• Osiris Therapeutics
The scope of the field is widening, with many organisations entering and collaborating. You see how.
Haematopoietic stem cell transplantation is an established treatment. Revenues from transplants of bone marrow, peripheral blood and umbilical cord blood form much of the market in 2012. Those activities form a beginning, with many advances possible by 2020.
There are many commercial opportunities in stem cells, with high revenues possible from 2012 to 2022. New products will change medicine. Our report shows you and explains.
Forecasts, market shares, developmental trends, commercial news and discussions
In visiongain’s report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), company profiles and discussions of R&D activities. You receive 40 tables, 20 charts and six research interviews.
For more information kindly visit :
Stem Cell Technologies: World Market Outlook 2012-2022
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter: http://twitter.com/#!/Sandhya3B